New Clinical Application of Henlius PD-L1 ADC-HLX43 in China Amidst Data Overload
HLX43 for injection is an innovative targeted PD-L1 antibody-drug conjugate (ADC) developed in collaboration between Henlius Biotech Co., Ltd. and Suzhou Yilian Biotechnology Co., Ltd. This drug is based on a fully humanized IgG1 anti-PD-L1 monoclonal antibody, conjugated with a novel tripeptide linker and a topoisomerase I inhibitor (derived from camptothecin compounds), forming a stable … Read more